
==== Front
Adv Sci (Weinh)
Adv Sci (Weinh)
10.1002/(ISSN)2198-3844
ADVS
Advanced Science
2198-3844
John Wiley and Sons Inc. Hoboken

34382344
10.1002/advs.202100727
ADVS2832
Review
Reviews
Ten Years of EWAS
Wei Siyu 1 2 *
Tao Junxian 1 2 *
Xu Jing 1 2 *
Chen Xingyu 1
Wang Zhaoyang 1
Zhang Nan 1
Zuo Lijiao 1
Jia Zhe 1
Chen Haiyan 1
Sun Hongmei 1
Yan Yubo 1
Zhang Mingming 1
Lv Hongchao 1
Kong Fanwu 2 3
Duan Lian 2 4
Ma Ye 1 2
Liao Mingzhi 2 5
Xu Liangde 2 6
Feng Rennan 2 7
Liu Guiyou 2 8
Project The EWAS 2
Jiang Yongshuai https://orcid.org/0000-0002-7163-6554
1 2 jiangyongshuai@hrbmu.edu.cn

1 College of Bioinformatics Science and Technology Harbin Medical University Harbin 150081 China
2 The EWAS Project Harbin China
3 Department of Nephrology The Second Affiliated Hospital Harbin Medical University Harbin 150001 China
4 The First Affiliated Hospital of Wenzhou Medical University Wenzhou 325000 China
5 College of Life Sciences Northwest A&F University Yangling Shanxi 712100 China
6 School of Biomedical Engineering Wenzhou Medical University Wenzhou 325035 China
7 Department of Nutrition and Food Hygiene Public Health College Harbin Medical University Harbin 150081 China
8 Beijing Institute for Brain Disorders Capital Medical University Beijing 100069 China
* E‐mail: jiangyongshuai@hrbmu.edu.cn

11 8 2021
10 2021
8 20 10.1002/advs.v8.20 210072711 5 2021
22 2 2021
© 2021 The Authors. Advanced Science published by Wiley‐VCH GmbH
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Abstract

Epigenome‐wide association study (EWAS) has been applied to analyze DNA methylation variation in complex diseases for a decade, and epigenome as a research target has gradually become a hot topic of current studies. The DNA methylation microarrays, next‐generation, and third‐generation sequencing technologies have prepared a high‐quality platform for EWAS. Here, the progress of EWAS research is reviewed, its contributions to clinical applications, and mainly describe the achievements of four typical diseases. Finally, the challenges encountered by EWAS and make bold predictions for its future development are presented.

Epigenome‐wide association study (EWAS) is applied to analyze DNA methylation variation in complex diseases for a decade, which is accompanied by advances and challenges. This review discusses the research process of EWAS, its application in biology and clinical translation. It also concludes with an analysis regarding the current limitations of EWAS and a forecast of its future.

epigenome‐wide association study (EWAS)
epigenetics
DNA methylation
Mathematical Tianyuan Fund of the National Natural Science Foundation of China12026414 National Natural Science Foundation of China 10.13039/501100001809 92046018 31970651 Innovation and Entrepreneurship Training Program for College Students of Heilongjiang Province in 2020S202010226092X source-schema-version-number2.0
cover-dateOctober 20, 2021
details-of-publishers-convertorConverter:WILEY_ML3GV2_TO_JATSPMC version:6.0.8 mode:remove_FC converted:21.10.2021
S. Wei , J. Tao , J. Xu , X. Chen , Z. Wang , N. Zhang , L. Zuo , Z. Jia , H. Chen , H. Sun , Y. Yan , M. Zhang , H. Lv , F. Kong , L. Duan , Y. Ma , M. Liao , L. Xu , R. Feng , G. Liu , T. E. Project , Y. Jiang , Ten Years of EWAS. Adv. Sci. 2021, 8 , 2100727. 10.1002/advs.202100727
==== Body
pmc1 Introduction

1.1 Background

It has been 10 years since the concept of EWAS was introduced, and the number of EWASs on common diseases has shown an increasing trend. Similar to genome‐wide association study (GWAS), EWAS is a widely used method for identifying biomarkers in populations and discovering molecular mechanisms of disease risk.[ 1 ] EWAS aims to use a variety of microarray‐based or sequencing‐based analysis techniques to obtain the association between epigenetic markers and phenotypes, which can ultimately explain the cause of the disease better and promote the development of new therapies and diagnostic methods.[ 2 ]

1.2 Rationale

Epigenetics is a branch of genetics, which aims to study the regulation of genes and other genetic factors in eukaryotes, covering DNA methylation, histone modification, etc.[ 3 , 4 , 5 ] In recent years, the variation of the epigenome has become a new research direction, and the most typical epigenetic mark is DNA methylation.[ 6 ] Phenotypically affected cases can be distinguished from normal samples based on the pattern of changes in DNA methylation, and this approach is known as EWAS. The commonly used EWAS analysis process usually starts with a reasonable hypothesis. Then a suitable population and tissue sample is selected. Blood samples are often used as it is difficult to obtain disease‐related tissue in most cases. However, blood DNA methylation patterns may yield different conclusions than those of tissue, so careful validation is required when using blood as a proxy. Next, it is important to choose a reasonable DNA methylation microarray or sequencing technology for factors such as experimental protocol and cost. The results are then validated and confounding factors are removed. When analyzing methylation data, it is important to focus on regional variation, identify differentially methylated regions and perform clustering analysis of CpG sites. Afterward, functional enrichment analysis will be performed to further understand the mechanisms of disease. Finally, visualization of all the analysis results is carried out in order to show them in a more intuitive way[ 7 ] (Figure 1 ).

Figure 1 Common analysis process of EWAS.

1.3 Aim

The purpose of this article is to review the important findings of EWASs in biology and clinical translation. We reviewed the origin and research process of EWAS, and summarized the findings of four typical diseases. At the end of this review, we analyzed the limitations of the current experimental design and made predictions about the future of EWAS.

2 Research Process of EWAS

EWAS is, in particular, intriguing as a method for studying the pathogenesis of complex diseases and commonly used to analyze methylation modifications and histone modifications etc. DNA methylation is currently the most studied, which is partly due to the better chemical and temporal stability of DNA methylation and the limitations of the research tools.[ 8 , 9 , 10 ] DNA methylation is a covalent modification with relatively good chemical stability due to the covalent binding of methyl to CpG dinucleotides.[ 11 , 12 ] From the other point of view, studies have demonstrated the temporal stability of DNA methylation.[ 13 , 14 ] In terms of the development of technical tools, there are several well established and reliable methods for the identification of DNA methylation, such as bisulfite conversion. And unlike histone modification, it is not lost during the DNA extraction process.[ 15 , 16 , 17 ] These advantages are the reason why DNA methylation has so far been the main object of study in EWAS. In the future, as research techniques advance, other epigenetic modifications will also be widely used.

Among the methods for analyzing methylation levels, Illumina microarrays are the most widely used. It was found that in the presence of bisulfite, unmethylated cytosines of genomic DNA can be converted to uracil, while methylated cytosines remain in the cytosine state.[ 18 ] Using the same principle, the Illumina Infinium HumanMethylation27 BeadChip (27k) used an Infinium I probe, while the Illumina Infinium HumanMethylation450 BeadChip (450 k) and Illumina HumanMethylationEPIC BeadChip (EPIC) used one of two probe types (Infinium I and Infinium II) to measure the methylation level of each CpG.[ 19 ] Each CpG site in Infinium I is operated by two probes, one to detect “methylated (M)” intensity and the other to detect “unmethylated (U)” intensity. Infinium II uses only one probe per CpG site to distinguish methylation intensity. The methylation level of a CpG site can be expressed as a Beta value, calculated as β = M / (M + U + α), where α is a constant offset. For Illumina microarrays, α is usually given as 100.[ 20 , 21 ] Beta values range from 0 (completely unmethylated) to 1 (completely methylated), corresponding to the percentage of cells with CpG methylation.[ 22 ] Beta mixture quantile normalization (BMIQ) indicates that a beta value greater than or equal to 0.75 is considered fully methylated. Beta value less than or equal to 0.25 is considered fully unmethylated. Beta value between 0.25 and 0.75 is considered hemimethylated.[ 23 , 24 ]

In addition to Illumina microarrays, whole genome bisulfite sequencing (WGBS) is the most efficient method for determining the methylation status of the genome and is also the most widely used method for EWAS in next‐generation sequencing.[ 25 , 26 ] WGBS also exploits the principle that bisulfite can selectively deaminate cytosines.[ 27 ] Following bisulfite treatment, polymerase chain reaction (PCR) amplification and next‐generation sequencing will be performed. Finally, untreated sequences are compared to bisulfite‐treated sequences to determine which nucleotide sites are methylated.[ 28 ] Single molecule real time (SMRT) sequencing technology in the third‐generation sequencing allows direct detection of DNA methylation without the need for bisulfite conversion. In SMRT sequencing, DNA polymerase catalyses the binding of fluorescently labelled nucleotides to complementary nucleic acid strands. Information on polymerase kinetics is derived from the arrival time and duration of the resulting fluorescent pulse. Since various modifications have different effects on polymerase kinetics, the kinetic signal can be used to identify methylation levels.[ 29 ]

Innovations in epigenetic methods and the reduction in the cost of EWAS have contributed to the rapid development of research. This contributes to the fact that the number of EWASs on common diseases is increasing every year (Figure 2 ). So far, DNA methylation microarrays, next‐generation sequencing and third‐generation sequencing remain the common methods for doing high‐throughput EWAS analysis.

Figure 2 EWAS literature timeline. From 2011 to the end of 2020, the cumulative number of EWAS‐related publications per year. The pie chart shows the platforms used by EWASs in these publications.

2.1 Illumina 27k

Early work on EWAS used the Illumina 27k, which contains 27 578 individual CpG loci distributed across 14 495 genes, accounting for <0.1% of the 28 million CpG loci in the human genome.[ 30 ] Illumina 27k was early applied to researches on common complex diseases, the effects of drug exposure on human DNA methylation and the prediction of cancer risk.[ 31 , 32 , 33 , 34 ] These studies were at that time all achieving milestones and the high accuracy of Illumina 27k has been demonstrated, leading to the conclusion that Illumina 27k is feasible for most experiments. In a study shortly after the introduction of EWAS, Breitling et al. used Illumina 27k to explore differences in DNA methylation associated with smoking.[ 35 ] A smoker‐specific hypermethylation site cg03636183 (F2RL3), which had never been identified, was found to be strongly associated with smoking‐induced disease.[ 36 ] However, due to the small number of samples and controls used in experiments, replicate experiments are still required to improve the accuracy of the results. Due to the lack of coverage of CpG loci in Illumina 27k and the small experimental sample size, there are more valuable CpG loci yet to be analyzed, which will need to be confirmed in future studies.

2.2 Illumina 450k

As experimental techniques continue to be refined, the most widely used methylation microarray is the Illumina 450k, which contains more than 485 000 methylation sites, covering 94% of Illumina 27k microarray, as well as involves CpG sites on CpG island shores, 5'UTR, 3'UTR, first exon region, and promoter regions.[ 16 , 37 ]. The Illumina 450k is the most commonly used tool for EWAS due to its wide coverage. After several years of application, researchers have recognized 1460 smoking‐related CpG sites in the EWASs with the use of the Illumina 450k.[ 38 ] The CpG loci (genes) highlighted in several different studies are cg05575921 (AHRR), cg03636183 (F2RL3), and cg19859270 (GPR15), which have been clearly linked to a variety of inflammation‐induced diseases, such as cardiovascular diseases, metabolic diseases and cancer,[ 39 , 40 , 41 ] There is no doubt that EWAS has made further a big stride forward with the assistance of Illumina 450k. Nevertheless, the Illumina 450k has its drawbacks. For example, its methylation site coverage is far from complete. Illumina has now released the EPIC, with new content specifically targeting regions lacking in 450k.

2.3 Illumina EPIC

Illumina EPIC detects the methylation status of approximately 868 564 CpG sites across the human genome, including more than 90% of the original 450K microarray (most of the loci that are not involved have been shown to perform poorly) and an additional 413 745 sites. Compared to Illumina 450k, not only does EPIC maintain comprehensive coverage of CpG islands and gene promoter regions, it also adds probe coverage of enhancer regions and gene coding regions.[ 37 ] Advances in experimental techniques have made it possible to measure almost twice as many CpG sites in EPIC than in Illumina 450K and to accurately analyze the impact of DNA methylation on common diseases in a wider range of regulatory regions. In an EWAS using EPIC in 2019, six new CpG loci (genes) were revealed, including cg17739917 (RARA), cg14051805 (FSIP1), cg12956751 (ALPP), cg22996023 (PIK3R5), cg07741821 (KIAA0087), and cg05086879 (MGAT3), to be strongly associated with cancer production and progression.[ 42 ] In recent years, there has been a growing number of EWASs using EPIC, which has become an indispensable tool for the study of epigenetic modifications with respect to human development and disease.[ 43 , 44 ]

2.4 Next‐Generation Sequencing

During the past 15 years, next‐generation sequencing (NGS) has experienced high‐speed development.[ 45 , 46 ] NGS has significantly reduced sequencing costs compared to Sanger sequencing, while increasing sequencing speed and maintaining high accuracy.[ 47 ] The emergence of NGS technologies has greatly influenced the development of epigenomic research and enhanced the understanding of biology and disease. One of the more widely used techniques is whole genome bisulfite sequencing (WGBS), which converts epigenetic differences into sequence differences and is used for genome‐wide DNA methylation detection.[ 28 , 48 ] The first study using WGBS to investigate Down syndrome (DS) found thousands of differentially methylated regions, with RUNX1 being the most significant factor altering epigenetic modifications in DS.[ 49 ] Although the advantages of next‐generation sequencing are huge, it is much shorter than the first‐generation sequencing technology in terms of sequence read length, which also gives room for the development of third‐generation sequencing.

2.5 Third‐Generation Sequencing

The advantages of third‐generation sequencing over next‐generation sequencing technology involve faster sequencing, higher accuracy, and direct detection of DNA methylation.[ 50 ] In addition to its long read lengths, the PacBio SMRT sequencing technology in third‐generation sequencing, more importantly, allows the identification of methylation sites for epigenetic studies and is currently used in EWAS.[ 29 , 51 , 52 , 53 , 54 ] In a recent EWAS using single‐molecule real‐time bisulfite sequencing (SMRT‐BS) to assess the impact of methylation of smoking‐associated regions on schizophrenia, allele‐specific methylation regions were identified in the smoking‐affected genes AHRR and IER3.[ 55 ] Methylation CpG loci found at AHRR (cg05575921) and IER3 (cg06126421) have been shown to be significantly associated with smoking, and be useful in assessing lung cancer risk in the smoking population.[ 56 , 57 , 58 ] The results suggest that the prediction model based on DNA methylation which incorporates allele‐specific information can be applied with higher accuracy in disease research and clinical settings. As the third‐generation sequencing technology is gradually demonstrating its unique advantages, it is being used more and more in the field of epigenetics.

3 A Decade of EWAS Achievements

EWAS provides a systematic approach to identify epigenetic variations as biomarkers in complex diseases.[ 59 , 60 ] Biomarkers play a role in disease identification, early diagnosis, the search for drug targets and the monitoring of drug response. In recent years, it has been found that epigenomes are more likely to serve as biomarkers than transcriptomes due to their stability.[ 61 ] Exploring and discovering valuable epigenetic biomarkers is gradually becoming a hot topic in disease research.[ 6 ] Driven by this situation, a wide variety of EWAS‐related databases and tools have been created in response to the trend.

3.1 Prediction of Disease Risk

EWAS can be used to predict specific disease risk by identifying specific DNA methylation loci as biomarkers.[ 62 , 63 ] In some heritable diseases, disease‐specific biomarkers have been identified by correlating specific epigenetic traits across generations with disease.[ 64 ] In this way, it is possible to determine the likelihood of the disease before it actually strikes. A study developed a methylation risk score (MRS) based on levels of methylation change. Researchers used this score together with information on 187 CpG loci associated with obesity to predict the risk of developing type 2 diabetes (T2D) in the future. The research results suggest that the MRS predicts T2D over traditional evaluation criteria like body mass index (BMI).[ 65 ] Epigenetic markers are emerging as valuable predictors of human disease susceptibility, and are expected to be widely used in clinical trials in the future.

3.2 Early Diagnosis of Disease

Early diagnosis of the disease in a timely manner will greatly improve the outcome of the disease treatment. Indicating biomarkers early in the disease process can help alter the disease process or even stop its progression.[ 66 ] Differentially methylated regions associated with autism spectrum disorders (ASD) were detected in cord blood in an EWAS.[ 67 ] This study explains the progression of ASD from an epigenetic standpoint and provides new perspectives for the early diagnosis of ASD. The accurate identification of biomarkers that can be used for early diagnosis is even more important in the treatment of cancer. An EWAS has identified three CpG loci that can be used as biomarkers for the early diagnosis of colorectal cancer (CRC).[ 68 ] Among them, cg04036920 and cg14472551 are located near the KIAA1549L transcription start site, another CpG site, cg12459502, is located in the BCL2 body region, and all of them have high sensitivity. To date, the use of epigenetic biomarkers for early diagnosis in the clinical setting is not widespread, and biomarkers with higher accuracy are still to be discovered.

3.3 Identifying Drug Targets

Epigenetic drugs, as a novel therapeutic tool, are currently used mostly in cancer research. One effective way to fight cancer is to inhibit methylation, and epigenetic drugs can have an impact on DNA methylation patterns.[ 69 , 70 ] Several epigenetic drugs targeting histone methyltransferases and DNA methyltransferases are currently available for the treatment of many types of cancer.[ 71 ] For instance, Zebularine, Azacitidine, and Chaetocin have been broadly used in the clinical practice.[ 72 ] Epigenetic drugs are also involved in the application of neurological diseases, immunological diseases, and metabolic diseases. In an EWAS analyzing differential DNA methylation associated with childhood asthma, several genes (loci) were confirmed as drug targets, including IL5RA (cg01310029, cg10159529), and KCNH2 (cg24576940, cg23147443, cg18666454).[ 73 ] These targets have been widely used in a variety of drugs. KCNH2 is the target of amiodarone hydrochloride, dofetilide, and sotalolol, IL5RA is the target of Benralizumab, a drug used in severe asthma patients.[ 74 ] From these findings, it is clear that EWAS plays an important role in the identification of novel drug targets.

3.4 Measuring Drug Response by Monitoring Drug‐Induced Epigenetic Changes

Examining drug‐induced epigenetic changes is a novel way to measure drug response and evaluate prognostic ability in recent years. As epigenetic markers can offer additional perspectives on changes in biological processes, they can provide a better framework for the study of events at different stages. Longitudinal methylation studies are of great advantage in this regard.[ 75 ] The main advantage is that it can explain interindividual differences in response after drug use, which is important for determining whether the drug accurately alters the response pathway associated with the disease.[ 76 ] This is finally used as a criterion for drug replacement or improvement.[ 77 ] In an epigenomic study on small cell lung cancer (SCLC) in 2020, the association between drug response and DNA methylation was analyzed for 526 pharmaceutical agents.[ 78 ] Numerous of these drugs exhibit a strong association with TREX1 methylation and expression. Targeting the epigenetic mechanisms of TREX1 may be a new way to develop novel antitumor drugs.

3.5 The Collation of Data and Knowledge Facilitates the Researcher

As epigenetics is demonstrating a strong influence in the study of complex diseases, the new development of EWAS‐related databases provides researchers with a powerful tool. In 2013, EWASdb was released as the first database to store EWAS results, allowing researchers to look for epigenetic association results between diseases and DNA methylation.[ 79 ] EWASdb contains 1319 EWASs results associated with 302 diseases/phenotypes. Furthermore, it can also search for DNA methylation markers, KEGG pathways, and GO categories that are significantly associated with certain diseases/phenotypes, which is definitely beneficial to researchers. Shortly afterward, the EWAS Atlas, a comprehensive database of EWAS knowledge, was launched.[ 80 ] EWAS Atlas selects, organizes, standardizes, and presents EWAS knowledge from a wide range of publications dedicated to helping researchers understand the molecular mechanisms of epigenetic modifications. Recently, the release of the EWAS Data Hub has provided a tremendous support in resolving epigenetic mechanisms.[ 81 ] It collects DNA methylation data from 75 344 samples (across 81 tissue/cell types, 6 ancestry categories, and 67 diseases) and uses efficient normalization methods to eliminate batch effects. All of these data resources have been used extensively in various EWAS experiments.

3.6 The Development of Tools Promotes New Discoveries

The development of practical tools related to EWAS also provides researchers with a convenient means to do so. These tools mainly perform the following functions: 1) identification of differentially methylated regions/loci (e.g., HPG‐DHunter, DMRcaller), 2) analysis of the association between epigenetic variation and disease/phenotype (e.g., EWAS2.0, EWAS1.0), 3) comprehensive analysis of DNA methylation data (e.g., GLINT, TABSAT), 4) prediction of histone modifications and DNA methylation level (e.g., Pancancer DNA Methylation Trackhub, Epigram), 5) prediction of complex traits based on methylation (e.g., TANDEM, OmicKriging), 6) identification of differential cell types based on methylation (e.g., CellDMC, BPRMeth), and 7) methylation data processing and normalization (e.g., omicsPrint, FuntooNorm). The following list (Table 1 ) of tools is organized according to the functionality of the tool, which includes function profile, the year of release, details about the implementation, such as programming language (R, Python, Java, etc.) or web‐based browser, software availability, and PubMed ID.

Table 1 Summary of EWAS‐related tools

Tools	Detail	Year	Implementation	Software availability	PMID	
Detection of differentially methylated region/loci	
HPG‐DHunter[ 172 ]	Detection of differentially methylated regions	2020	Software	https://grev‐uv.github.io/	32631226	
DMRcaller[ 173 ]	Differentially methylated regions caller	2018	R package	http://bioconductor.org/packages/DMRcaller/	29986099	
DiMmeR[ 174 ]	Discovery of multiple differentially methylated regions	2017	Java package	http://dimmer.compbio.sdu.dk	27794558	
MethylDMV [175]	Detection of differentially methylated regions	2017	R package	http://www.ams.sunysb.edu/∼pfkuan/softwares.html#methylDMV	27896998	
WFMM[ 176 ]	Identification of differentially methylated loci	2016	Software	https://biostatistics.mdanderson.org/SoftwareDownload	26559505	
MethylAction[ 177 ]	Detection of differentially methylated regions	2016	R package	http://jeffbhasin.github.io/methylaction	26673711	
AmpliMethProfiler[ 178 ]	Identification of methylated/unmethylated regions	2016	Python package	http://amplimethprofiler.sourceforge.net	27884103	
iDNA‐Methyl[ 179 ]	Identification of differentially methylated loci	2015	Webserver	http://www.jci‐bioinfo.cn/iDNA‐Methyl	25596338	
swDMR[ 180 ]	Detection of differentially methylated regions	2015	Software	http://sourceforge.net/projects/swDMR	26176536	
EpiDiff[ 181 ]	Identification of differential epigenetic modification regions	2013	Software	http://bioinfo.hrbmu.edu.cn/epidiff	24109772	
Analysis of the association between epigenetic variation and disease/phenotype	
EWAS2.0[ 182 ]	Analysis of the association between epigenetic variation and disease/phenotype	2018	Software	http://www.ewas.org.cn	29566144	
EWAS1.0[ 183 ]	Analysis of the association between epigenetic variation and disease/phenotype	2016	Software	http://www.ewas.org.cn	27892496	
DEMGD[ 184 ]	Extraction of associations of methylated genes and diseases	2013	Webserver	http://www.cbrc.kaust.edu.sa/demgd	24147091	
Comprehensive Analysis of DNA Methylation Data	
GLINT[ 185 ]	Analysis of high‐throughput DNA‐methylation array data	2017	Python package	https://github.com/cozygene/glint/releases	28177067	
TABSAT[ 186 ]	Analysing targeted bisulfite sequencing data	2016	Software	http://demo.platomics.com	27467908	
BioVLAB‐mCpG‐SNP‐EXPRESS[ 187 ]	Various integrated analyses such as methylation vs. gene expression and mutation vs methylation are performed	2016	Webserver	http://biohealth.snu.ac.kr/software/biovlab_mcpg_snp_express	27477210	
RefFreeDMA[ 188 ]	Differential DNA methylation analysis	2015	Software	http://RefFreeDMA.computational‐epigenetics.org	26673328	
MethGo[ 189 ]	Analyzing whole‐genome bisulfite sequencing data	2015	Python package	http://paoyangchen‐laboratory.github.io/methgo	26680022	
MethylSig[ 190 ]	DNA methylation analysis	2014	R package	http://sartorlab.ccmb.med.umich.edu/software	24836530	
Methy‐pipe[ 191 ]	Whole genome bisulfite sequencing data analysis	2014	Software	http://sunlab.lihs.cuhk.edu.hk/methy‐pipe	24945300	
RnBeads[ 192 ]	DNA methylation analysis	2014	Software	http://rnbeads.mpi‐inf.mpg.de	25262207	
APEG[ 193 ]	Analyze the functions of epigenomic modifications	2013	Software	http://systemsbio.ucsd.edu/apeg	24339764	
GBSA[ 194 ]	Analysing whole genome bisulfite sequencing data	2013	Python package	http://ctrad‐csi.nus.edu.sg/gbsa	23268441	
EpiExplorer[ 195 ]	Analysis of large epigenomic datasets	2012	Software	http://epiexplorer.mpi‐inf.mpg.de	23034089	
IMA [196]	Analysis of Illumina 450K	2012	R package	http://www.rforge.net/IMA	22253290	
BiQ analyzer HT[ 197 ]	Locus‐specific analysis of DNA methylation by high‐throughput bisulfite sequencing	2011	Software	http://biq‐analyzer‐ht.bioinf.mpi‐inf.mpg.de	21565797	
CNAmet[ 198 ]	Comprehensive analysis of high‐throughput copy number, DNA methylation and gene expression data	2011	R package	http://csbi.ltdk.helsinki.fi/CNAmet	21228048	
Methyl‐analyzer[ 199 ]	DNA methylation analysis	2011	Python package	http://github.com/epigenomics/methylmaps	21685051	
Prediction of histone modifications and DNA methylation level	
Pancancer DNA Methylation Trackhub[ 200 ]	Depicting the overall DNA methylation status	2018	Webserver	http://maplab.cat/tcga_450k_trackhub	29605850	
LR450K [201]	Prediction of methylation levels	2016	R package	http://wanglab.ucsd.edu/star/LR450K	26883487	
Epigram[ 202 ]	Predicts histone modification and DNA methylation patterns from DNA motifs	2015	Software	http://wanglab.ucsd.edu/star/epigram	25240437	
MLML[ 203 ]	Estimates of DNA methylation and hydroxymethylation levels	2013	Software	http://smithlab.usc.edu/software/mlml	23969133	
DMEAS[ 204 ]	Estimates methylation levels	2013	Software	http://sourceforge.net/projects/dmeas/files	23749987	
Prediction of complex traits	
TANDEM[ 205 ]	Measure drug response	2016	R package	http://ccb.nki.nl/software/tandem	27587657	
OmicKriging[ 206 ]	Prediction of complex traits, such as disease risk or drug response	2014	R package	http://www.scandb.org/newinterface/tools/OmicKriging.html	24799323	
ITFoM[ 207 ]	Prediction of health risks, progression of diseases, and selection and efficacy of treatments	2013	Webserver	http://www.itfom.eu	23165094	
Identification of differential cell types	
BPRMeth [208]	Predicting gene expression levels or clustering genomic regions or cells	2018	R package	http://bioconductor.org/packages/BPRMeth	29522078	
CellDMC[ 209 ]	Identification of differentially methylated cell types	2018	R package	https://github.com/sjczheng/EpiDISH	30504870	
eFORGE[ 210 ]	Identifying cell type‐specific signal	2016	Webserver	http://eforge.cs.ucl.ac.uk	27851974	
Methylation data processing and normalization	
OmicsPrint[ 211 ]	Detection of data linkage errors in multiple omics studies	2018	R package	http://bioconductor.org/packages/omicsPrint	29420690	
FuntooNorm[ 212 ]	Normalization of DNA methylation data	2016	R package	https://github.com/GreenwoodLab/funtooNorm	26500152	
Beclear[ 213 ]	Correction of batch effects in DNA methylation data	2016	R package	http://bioconductor.org/packages/release/bioc/html/BEclear.html	27559732	
Jllumina[ 214 ]	Handling of 450 k and EPIC data	2016	Java package	http://dimmer.compbio.sdu.dk/download.html	28187410	
SMETHILLIUM[ 215 ]	Spatial normalization method for Illumina infinium HumanMethylation BeadChip	2011	R package	http://bioinfo.curie.fr/projects/smethillium	21493659	
John Wiley & Sons, Ltd.

4 Four Exemplars of EWAS Success

Published results of EWASs have addressed a variety of common diseases including autoimmune diseases (e.g., rheumatoid arthritis, asthma, and allergy), metabolic diseases (e.g., metabolic syndrome, obesity, and T2D), psychiatric disorders (e.g., alzheimer's disease, depression, and schizophrenia), and cancer (Figure 3 ). At this point, we highlight a subcategory from each of the four broad disease categories as a typical example to illustrate some of the significant advances that were brought about by the important findings of EWASs.

Figure 3 Word cloud of traits in EWASs. Top 100 traits in EWAS, including phenotypes, behaviors, environmental factors, cancer and noncancer diseases.

4.1 Rheumatoid Arthritis

Epigenetics plays an important role in the pathogenesis of autoimmune diseases. In the last decade, EWAS has contributed significantly to a better understanding of the pathogenic relevance of immune‐mediated diseases. The most representative one is rheumatoid arthritis (RA), a common autoimmune disease influenced by genetic factors and environmental exposures.[ 82 , 83 ]

4.1.1 Biological Significance

Thousands of differential methylation sites associated with RA have been observed in nearly a decade of EWASs.[ 84 , 85 , 86 ] The human major histocompatibility complex (MHC) has a strong epigenetic association with the pathogenesis of RA.[ 87 ] A recent study detected 74 unique methylated CpG loci in the MHC region, with 22 genes containing 32 of these differentially methylated CpG motifs. These genes are involved in the antigen presentation process as well as interfering with the role of immune cells in autoimmunity.[ 88 ] Another study also confirmed that differences in DNA methylation within the MHC region are strongly associated with RA progression.[ 89 ] In addition to the MHC region, immune cells also have epigenetic association with RA.

Cellular and humoral immunity are the primary pathways that lead to the production of autoantibodies by immune cells that secrete inflammatory factors.[ 90 ] Since RA is highly correlated with B, T, and other lymphocytes, accurate detection, and alteration of specific cell types can be achieved to effectively treat RA. Through an EWAS for RA, it was found that abnormal hypermethylation and hypomethylation of two loci, cg18972751 and cg03055671 (CD1C and TNFSF10), are associated with RA.[ 91 ] The overexpression of CD1C in B cells enhances self‐antigen reactivity, which is one of the main causes of RA pathogenesis.[ 92 ] TNFSF10 (also known as TRAIL) belongs to the tumor necrosis factor (TNF) superfamily of cytokines, and it has been shown that TRAIL acts as a barrier against autoimmunity in RA.[ 93 ] These results all clarify the causal relationship between epigenetic modifications and RA disease onset, while supporting the importance of epigenetics as a method to uncover novel molecular mechanisms in autoimmune diseases.

4.1.2 Clinical Translation

DNA methylation, as an epigenetic modification affected environmental exposures covering pharmacotherapy, has been widely used in the drug discovery. Although biologic drug therapies have made tremendous advances in RA, only a minority of patients have effective control of their disease.[ 94 , 95 ] Etanercept is the most common drug used to treat RA, and an experiment characterized five drug‐sensitive methylation sites associated with it.[ 96 , 97 ] Given that some biologics are expensive and ineffective to produce, it is increasingly important to provide patients with personalized treatments and medications for RA.

4.2 Metabolic Syndrome

Complex diseases like metabolic syndrome (MetS) have multiple pathogenic causes, such as epigenetic mechanisms (including DNA methylation and histone modifications) along with the role of environmental factors.[ 98 ] Among noncommunicable diseases, MetS has become one of the most morbid and mortal diseases.[ 99 ] MetS is a combination of several diseases, covering obesity and diabetes, which significantly increases the risk of death from hepatitis, cardiovascular disease, and cancer.[ 100 , 101 , 102 ] Due to the rapid development of EWAS in recent years, major breakthroughs have been made in the study of the etiology of MetS, factors influencing disease progression, and drug therapy.

4.2.1 Biological Significance

MetS is extensively influenced by environmental factors, and diet is one of the most routine environmental factors that everyone faces in their daily lives.[ 103 , 104 ] A number of diet‐influenced methylation sites have been identified as being involved in metabolism‐related regulatory pathways, including those related to lipid metabolism, immunity, and cellular differentiation.[ 105 , 106 , 107 ] One of the more investigated methylation sites, cg00574958, has shown significant correlation with MetS in several EWASs.[ 108 , 109 ] It was shown that carbohydrate intake leads to cg00574958 hypermethylation, which reduces the risk of MetS. Conversely, fat intake leads to cg00574958 hypomethylation, thereby increasing the risk of MetS.[ 110 ]

In an EWAS based on peripheral blood mononuclear cells (PBMC), methylation status of SOCS3 (cg18181703), a gene which participates in the regulation of leptin and insulin signaling, was found to be significantly associated with obesity and was inversely proportional to BMI.[ 105 ] Else, numerous studies have demonstrated that repression of SOCS3 expression holds promise for the treatment of metabolic diseases like obesity.[ 111 , 112 , 113 ] The contribution of epigenetics to T2D, a complex multifactorial disease, is even greater, with hundreds of methylation difference loci now identified.[ 114 , 115 , 116 ] cg06500161 (ABCG1) is a well‐studied and significantly associated methylation site for T2D.[ 117 ] The protein encoded by ABCG1 is involved in intracellular as well as extracellular signaling and lipid transport, where hypermethylation of this site increases the prevalence of MetS, T2D, and obesity.[ 98 ] In summary, the onset and development of MetS and related diseases (e.g., obesity and T2D) are to some extent caused by epigenetic modifications (e.g., DNA methylation).

4.2.2 Clinical Translation

The EWAS on MetS provides multiple pathways for clinical translation. First, lifestyles like dietary habits alter DNA methylation patterns to varying degrees. Through several EWASs, it is clear that vitamin D, fat and alcohol intake all have impacts on MetS. Moderate alcohol and tea consumption reduces the risk of T2D and obesity, but smoking and excessive dietary fat increase the likelihood of causing T2D.[ 118 , 119 , 120 ] Second, due to the addition of epigenetics, researchers have found promising epigenetic markers associated with T2D.[ 115 , 121 ] A study found that DNA methylation of ABCG1 (cg06500161) affects triglyceride levels, and a drug called Pemafibrate, developed based on ABCG1, showed a high‐quality effect in treating T2D.[ 122 , 123 ] Third, identifying the effects of therapeutic drugs on DNA methylation based on epigenetic approaches could lead to a better understanding of the physiological pathways impacted by the drugs.[ 124 ] This leads to the goal of promoting personalized therapies, developing novel diagnostic techniques and more effective medicines.[ 105 ]

4.3 Alzheimer's Disease

Alzheimer's disease (AD) is a neurodegenerative disease, the most prevalent form of dementia, affecting millions of people worldwide.[ 125 ] Although the identification of psychiatric‐associated differential methylation sites started late, with the gradual maturation of EWAS, impressive results have been demonstrated in recent years in AD.[ 126 , 127 ]

4.3.1 Biological Significance

The potential role of epigenetic mechanisms in AD has been gradually uncovered since the first EWAS that has identified 948 CpG loci associated with AD using Illumina 27k in 2012.[ 128 ] The differentially methylated sites cg11823178 and cg05066959 identified in the ANK1 gene have been clearly pointed out in several EWASs.[ 129 , 130 , 131 ] In addition, a large number of aberrantly methylated CpG site‐pending genes are enriched in the mitotic cell cycle regulation and Wnt signaling pathways, suggesting a hidden role for aberrant Wnt signaling in neurodegenerative diseases and promising a new drug target for AD treatment.[ 132 , 133 , 134 ]

Most EWASs for AD assess DNA methylation differences in brain tissue,[ 135 , 136 ] however, there are many sites identified in brain tissue that are not detected in blood, such as the early popular gene ANK1.[ 66 , 129 ] In a recent study, examining DNA methylation patterns in whole blood from AD patients, differential methylation regions were identified in gene HOXB6, and abnormal hypermethylation of sites within HOXB6 (cg17179862 and cg03803541) affected granulocyte and monocyte production.[ 137 ] Even more intriguingly, the same CpG sites also exhibit different or even opposite methylation patterns in the brain and blood. OXT (encoding oxytocin) is one of the most influential genes in the brain and blood for AD.[ 138 ] In brain tissue, 10 CpG sites of OXT show decreased methylation levels in AD patients.[ 139 ] Conversely, these sites detected elevated methylation levels in the peripheral blood. Although there are some patterns of association between the brain and blood, not all differences associated with AD in the blood are related to processes occurring in the brain, and the way in which they interact remains to be investigated.

4.3.2 Clinical Translation

Epigenetics has become an important area of research in the development of drug relocalization, and the identification of protein targets based on epigenetics is now becoming the mainstream of overcoming AD.[ 140 , 141 ] Screening from known AD drugs was performed to extract 14 epigenetic drugs for relocalization based on epigenetic drug‐target network (EP‐DTN).[ 142 ] There are currently no drugs that target abnormal DNA methylation loci in AD, but with the development of epigenomics and advances in pharmaceutical technology, epigenetic drugs will eventually be developed to effectively treat AD.

4.4 Breast Cancer

Breast cancer is the most common cancer in the female population, and its incidence is increasing every year.[ 143 , 144 ] A variety of environmental factors can contribute to the incidence of breast cancer, for instance, age, hormones, BMI, etc.[ 145 ] EWAS can effectively analyze the impact of these factors on breast cancer for the purpose of supplying diagnostic and therapeutic measures.

4.4.1 Biological Significance

Age is one of the risk factors for breast cancer.[ 146 ] Recent EWASs have reported that some methylation sites which change with age are associated with breast cancer risk and prognosis.[ 145 ] The first EWAS of age‐associated methylation changes showed that they were broadly spread throughout the genome.[ 146 ] Subsequent studies have cumulatively identified over eight hundred age‐related CpG loci associated with breast cancer.[ 14 , 147 ] These results all go some way to explaining the increase in breast cancer incidence with age.

In addition to age, hormone therapy (HT) is a recognized causative factor.[ 148 ] Several studies have shown that estrogen or other hormone exposure can also lead to changes in DNA methylation in the blood that can affect the risk of breast cancer.[ 149 , 150 ] An EWAS identified 694 CpG loci associated with estrogen exposure.[ 151 ] Another EWAS illustrated 527 CpG sites with altered levels of DNA methylation in HT users.[ 152 ] Twelve of these loci were all highly significant, such as cg01382688 (ARHGEF4). These findings all confirm that hormone exposure and epigenetic alterations are correlated, providing assistance in the prevention of breast cancer.

BMI may be implicated in a number of mechanisms to influence the development of breast cancer and its role should not be overlooked.[ 153 ] Increased DNA methylation at cg46801642 was found to be associated with a 1.35‐fold increase in breast cancer risk in an EWAS in 2020 using blood DNA samples.[ 154 ] In an EWAS of breast tissue, the methylation levels of 935 probes increased with increasing BMI and obesity was significantly associated with differential methylation in 21 CpG sites.[ 155 ] These studies suggest that BMI may affect methylation levels at sites associated with breast cancer.

4.4.2 Clinical Translation

Despite the remarkable success of current treatments for breast cancer, a number of patients' lives are hampered or suffer from cancer metastasis due to late detection. Extracting DNA from peripheral blood and analyzing its methylation change pattern help to find biomarkers for breast cancer risk and early detection.[ 156 ] This can definitely enhance the survival rate of patients significantly. Discoveries in recent years have demonstrated the potential of epigenetic studies to assess cancer risk.[ 157 ] An early study showed that reduced methylation levels of cg27091787 (HYAL2) were associated with an increased risk of breast cancer.[ 158 ] This was followed by the generation of a large number of EWASs for the identification of DNA methylation‐related biomarkers for early detection.[ 159 , 160 ] Although dozens of biomarkers have been revealed, most of them show only very limited distinguishing power.[ 157 ] Therefore, efforts are still needed to explore sensitive markers for the purpose of implementing effectively diagnostic and preventive strategies.

5 Discussion

We outline the development of methylation detection technologies over the last decade and then summarize the major discoveries together with associated resource tools generated by EWAS. We finally describe the biological significance and clinical translational applications of four typical diseases. In addition to these four well‐known disorders, EWAS provides strong support for the study of asthma and depression disorder in relation to methylation.

Asthma is a global disease that is influenced by environmental factors as well as epigenetic changes.[ 161 ] Several EWASs have been published in recent years to investigate asthma susceptibility and mechanisms. To date, experiments using nine cohorts have yielded a total of 179 CpG loci and 36 differentially methylated regions associated with asthma.[ 73 , 162 ] Most CpG loci have strong associations with eosinophils, effector T cells, memory T cells, and natural killer cells. Currently, the main research direction for asthma‐associated EWASs is drug development, and further evaluation of methylation variants will help in the typing of asthma, which is expected to enable personalized treatment.

Depression is a common psychiatric disorder that is thought to be influenced by a combination of genetics and environment. In 2018, three methylation loci associated with depressive symptoms were identified in an EWAS that used DNA methylation in blood to identify epigenetic mechanisms of depression.[ 163 ] cg04987734, cg12325605, and cg14023999 have all been associated with axon guidance pathways and may have an important role in assessing the pathology as well as the clinical role of depression.[ 164 ] In an EWAS last year based on the association between DNA methylation in brain tissue and depression, reliable CpG loci were identified in the YOD1 exon, PFKFB2 intron, UGT8, FNDC3B, and SLIT2 regions.[ 165 ] Of these, YOD1 has been shown to be associated with mechanisms of multiple neurodegenerative diseases and UGT8 is a known biomarker gene for depressed mood.[ 166 , 167 ] These CpG loci hold promise as epigenetic markers of depression and for application in clinical drug development trials.

Recent researches on complex diseases, covering cancer, have been supported by EWAS due to its ability to recognize epigenetic changes that are not possible with previous technologies. EWAS is more applied to the study of the influence of environmental factors on disease mechanisms, which provides a deeper understanding of the causes and progression of diseases so that more diverse therapeutic options can be generated to achieve the goal of precision medicine.

Despite the significant achievements of EWAS, its limitations are still significant and it will face numerous challenges in the future. 1) Since epigenetic modifications are mainly influenced by environment and genetics, methylation patterns at each CpG site may be highly variable across geographic regions and races. To date, Europeans have accounted for a large proportion of the numerous EWAS subjects, although studies of Asian and African ethnicities have increased in recent years, but not nearly as much as Europeans. It has been shown that certain DNA methylation patterns vary considerably by ethnicity,[ 168 , 169 , 170 ] which reinforces the importance of increasing the sample size and ethnic diversity of experiments, as well as to better achieve the goal of personalized treatment. 2) The number of factors that can influence epigenetic modifications is numerous, therefore high quality EWAS requires that confounding factors be considered in the design of experiments so that they can be effectively controlled in subsequent analyzes.[ 61 ] Because epigenetic modifications differ between cell types and tissue types, EWAS is sometimes confounded by the cellular heterogeneity or tissue specificity of the sample. Because of the different biological characteristics of cells from different sources, whether blood samples accurately reflect the methylation patterns of the target tissues needs further validation. 3) Since methylation changes are extremely influenced by the environment, longitudinal studies are needed to analyze how epigenetic modifications change before, after the onset and following pharmacological interventions.[ 171 ] Longitudinal studies allow for the detection of methylation levels in patients at multiple time points to determine the causal relationship between methylation and disease. Another advantage of longitudinal studies is the ability to access changes in epigenetic factors over the life cycle, which can help recognize biomarkers that precede the onset of disease. However, such EWAS are extremely rare because of the high costs involved and the long study duration. 4) To date, the vast majority of data sources used for EWAS are still supported by Illumina 27k or Illumina 450k, but they provide only a limited number of genomic regions, which may result in the loss of important methylation regions. The newly‐developed Illumina EPIC and three‐generation sequencing technologies have greatly improved this deficiency.[ 37 ] However, the application of the new technology is not yet widespread, so future research is expected to yield more comprehensive results.

In the future, EWAS needs to find appropriate ways to address these challenges. Research also needs to move focus from methylation site discovery to biological understanding and clinical translation. For example, discovering more accurate diagnostic modalities and novel therapeutic approaches. Epigenetic changes in complex diseases will still remain a major research topic in the coming years, and for the foreseeable future the results obtained from EWAS will have a considerable impact on clinical applications.

Conflict of Interest

The authors declare no conflict of interest.

Author Contributions

S.Y.W., J.X.T., and J.X. contributed equally to this work, they are joint first authors. Y.S.J. conceived and contributed the work. S.Y.W., J.X.T., J.X., X.Y.C., Z.Y.W., N.Z., L.J.Z., Z.J., H.Y.C., H.M.S., Y.B.Y., M.M.Z., and H.C.L. drafted and modified the manuscript. S.Y.W., J.X.T., J.X., F.W.K., L.D., Y.M., M.Z.L., L.D.X., R.N.F., and G.Y.L. are important contributors of the EWAS Project. The EWAS Project provided data support (http://www.ewas.org.cn or http://www.bioapp.org/ewasdb).

Acknowledgements

This work was supported by the Mathematical Tianyuan Fund of the National Natural Science Foundation of China (Grant No. 12026414); National Natural Science Foundation of China (Grant Nos. 92046018 and 31970651); Innovation and Entrepreneurship Training Program for College Students of Heilongjiang Province in 2020 (No. S202010226092X). The Author Contributions were amended on October 6, 2021 after initial online publication.

Siyu Wei has received his B.Sc. in Biomedical Engineering from Harbin Medical University in 2020 and is currently pursuing his M.Sc. in the College of Bioinformatics Science and Technology. Under the supervision of Prof. Yongshuai Jiang, he is dedicated to research related to epigenetics and statistical genetics.

Junxian Tao is a master in Harbin Medical University of College of Bioinformatics Science and Technology, where she has received the B.S. degree in biomedical engineering in 2020. She currently works on exploring markers’ effect of human complex traits and diseases under the guidance of Prof. Yongshuai Jiang.

Jing Xu has just completed a master's degree in Biomedical Engineering from Harbin Medical University in 2021 and will proceed to the degree of Ph.D. there. She has been working on the development and application of epigenetic association study software for risk early warning of major diseases and complex traits under the guidance of Prof. Yongshuai Jiang.
==== Refs
1 J. M. Flanagan , Methods Mol. Biol. 2015, 1238 , 51.25421654
2 V. K. Rakyan , T. A. Down , D. J. Balding , S. Beck , Nat. Rev. Genet. 2011, 12 , 529.21747404
3 A. Ganesan , Philos. Trans. R. Soc., B 2018, 373 , 1748.
4 B. E. Bernstein , A. Meissner , E. S. Lander , Cell 2007, 128 , 669.17320505
5 M. M. Suzuki , A. Bird , Nat. Rev. Genet. 2008, 9 , 465.18463664
6 M. Tanić , S. Beck , Curr. Opin. Genet. Dev. 2017, 42 , 48.28391083
7 K. B. Michels , A. M. Binder , S. Dedeurwaerder , C. B. Epstein , J. M. Greally , I. Gut , E. A. Houseman , B. Izzi , K. T. Kelsey , A. Meissner , A. Milosavljevic , K. D. Siegmund , C. Bock , R. A. Irizarry , Nat. Methods 2013, 10 , 949.24076989
8 M. Forest , K. J. O'donnell , G. Voisin , H. Gaudreau , J. L. Macisaac , L. M. Mcewen , P. P. Silveira , M. Steiner , M. S. Kobor , M. J. Meaney , C. M. T. Greenwood , Epigenetics 2018, 13 , 19.29381404
9 R. P. Talens , D. I. Boomsma , E. W. Tobi , D. Kremer , J. W Jukema , G. Willemsen , H. Putter , P. E Slagboom , B. T. Heijmans , FASEB J. 2010, 24 , 3135.20385621
10 L. Shen , R. A. Waterland , Curr. Opin. Clin. Nutr. Metab. Care 2007, 10 , 576.17693740
11 Z. D. Smith , H. Gu , C. Bock , A. Gnirke , A. Meissner , Methods 2009, 48 , 226.19442738
12 T. H. Bestor , Hum. Mol. Genet. 2000, 9 , 2395.11005794
13 H.‐M. Byun , F. Nordio , B. A. Coull , L. Tarantini , L. Hou , M. Bonzini , P. Apostoli , P. A. Bertazzi , A. Baccarelli , PLoS One 2012, 7 , e39220.22745719
14 J. M. Flanagan , M. N. Brook , N. Orr , K. Tomczyk , P. Coulson , O. Fletcher , M. E. Jones , M. J. Schoemaker , A. Ashworth , A. Swerdlow , R. Brown , M. Garcia‐Closas , Cancer Epidemiol., Biomarkers Prev. 2015, 24 , 221.25371448
15 R. Lister , M. Pelizzola , R. H. Dowen , R. D Hawkins , G. Hon , J. Tonti‐Filippini , J. R. Nery , L. Lee , Z. Ye , Q.‐M. Ngo , L. Edsall , J. Antosiewicz‐Bourget , R. Stewart , V. Ruotti , A. H Millar , J. A. Thomson , B. Ren , J. R. Ecker , Nature 2009, 462 , 315.19829295
16 M. Bibikova , B. Barnes , C. Tsan , V. Ho , B. Klotzle , J. M. Le , D. Delano , L. Zhang , G. P. Schroth , K. L. Gunderson , J.‐B. Fan , R. Shen , Genomics 2011, 98 , 288.21839163
17 M. Stevens , J. B. Cheng , D. Li , M. Xie , C. Hong , C. L. Maire , K. L. Ligon , M. Hirst , M. A. Marra , J. F. Costello , T. Wang , Genome Res. 2013, 23 , 1541.23804401
18 Q. Lin , W. Wagner , M. Zenke , Methods Mol. Biol. 2013, 1049 , 21.23913206
19 M. C. Wu , P. F. Kuan , Methods Mol. Biol. 2018, 1708 , 303.29224151
20 S. Zhao , W. Jing , D. C. Samuels , Q. Sheng , Y. Shyr , Y. Guo , Briefings Bioinf. 2018, 19 , 765.
21 P. Du , X. Zhang , C.‐C. Huang , N. Jafari , W. A. Kibbe , L. Hou , S. M. Lin , BMC Bioinf. 2010, 11 , 587.
22 M. Bibikova , Genome Res. 2006, 16 , 383.16449502
23 A. E. Teschendorff , F. Marabita , M. Lechner , T. Bartlett , J. Tegner , D. Gomez‐Cabrero , S. Beck , Bioinformatics 2013, 29 , 189.23175756
24 Z. Wang , X. Wu , Y. Wang , BMC Bioinf. 2018, 19 , 115.
25 E.‐J. Lee , J. Luo , J. M. Wilson , H. Shi , Cancer Lett. 2013, 340 , 171.23200671
26 N. Ulahannan , J. M. Greally , Epigenet. Chromatin 2015, 8 , 5.
27 M. Frommer , L. E. Mcdonald , D. S. Millar , C. M. Collis , F. Watt , G. W. Grigg , P. L. Molloy , C. L. Paul , Proc. Natl. Acad. Sci. USA 1992, 89 , 1827.1542678
28 Y. Li , T. O. Tollefsbol , Methods Mol. Biol. 2011, 791 , 11.21913068
29 B. A. Flusberg , D. R. Webster , J. H. Lee , K. J. Travers , E. C. Olivares , T. A. Clark , J. Korlach , S. W. Turner , Nat. Methods 2010, 7 , 461.20453866
30 M. Bibikova , J. Le , B. Barnes , S. Saedinia‐Melnyk , L. Zhou , R. Shen , K. L. Gunderson , Epigenomics 2009, 1 , 177.22122642
31 Z. Xu , S. C. E. Bolick , L. A. Deroo , C. R. Weinberg , D. P. Sandler , J. A. Taylor , J. Natl. Cancer Inst. 2013, 105 , 694.23578854
32 J. Conroy , P. A. Mcgettigan , D. Mccreary , N. Shah , K. Collins , B. Parry‐Fielder , M. Moran , D. Hanrahan , T. W. Deonna , C. M. Korff , D. Webb , S. Ennis , S. A. Lynch , M. D. King , Epilepsia 2014, 55 , 858.24828792
33 A. R. Halvorsen , Å. Helland , T. Fleischer , K. M. Haug , G. I. Grenaker Alnæs , D. Nebdal , R. G. Syljuåsen , N. Touleimat , F. Busato , J. Tost , A. B. Sætersdal , A.‐L. Børresen‐Dale , V. Kristensen , H. Edvardsen , Int. J. Cancer 2014, 135 , 2085.24658971
34 H. M. Abdolmaleky , S. Nohesara , M. Ghadirivasfi , A. W. Lambert , H. Ahmadkhaniha , S. Ozturk , C. K. Wong , R. Shafa , A. Mostafavi , S. Thiagalingam , Schizophr. Res. 2014, 152 , 373.24411530
35 L. P. Breitling , R. Yang , B. Korn , B. Burwinkel , H. Brenner , Am. J. Hum. Genet. 2011, 88 , 450.21457905
36 S. Ando , H. Otani , Y. Yagi , K. Kawai , H. Araki , S. Fukuhara , C. Inagaki , Respir. Res. 2007, 8 , 31.17433115
37 R. Pidsley , E. Zotenko , T. J. Peters , M. G. Lawrence , G. P. Risbridger , P. Molloy , S. Van Djik , B. Muhlhausler , C. Stirzaker , S. J. Clark , Genome Biol. 2016, 17 , 208.27717381
38 X. Gao , M. Jia , Y. Zhang , L. P. Breitling , H. Brenner , Clin. Epigenet. 2015, 7 , 113.
39 F. Guida , T. M. Sandanger , R. Castagné , G. Campanella , S. Polidoro , D. Palli , V. Krogh , R. Tumino , C. Sacerdote , S. Panico , G. Severi , S. A. Kyrtopoulos , P. Georgiadis , R. C. H. Vermeulen , E. Lund , P. Vineis , M. Chadeau‐Hyam , Hum. Mol. Genet. 2015, 24 , 2349.25556184
40 M. V. Dogan , B. Shields , C. Cutrona , L. Gao , F. X. Gibbons , R. Simons , M. Monick , G. H. Brody , K. Tan , S. R. Beach , R. A. Philibert , BMC Genomics 2014, 15 , 151.24559495
41 W. Besingi , Å. Johansson , Hum. Mol. Genet. 2014, 23 , 2290.24334605
42 V. Barcelona , Y. Huang , K. Brown , J. Liu , W. Zhao , M. Yu , S. L. R. Kardia , J. A. Smith , J. Y. Taylor , Y. V. Sun , Epigenetics 2019, 14 , 383.30915882
43 J. W. Abdulrahim , L. C. Kwee , E. Grass , I. C. Siegler , R. Williams , R. Karra , W. E. Kraus , S. G. Gregory , S. H. Shah , J. Am. Heart Assoc. 2019, 8 , e013228.31642367
44 M. W. Logue , M. W. Miller , E. J. Wolf , B. R. Huber , F. G. Morrison , Z. Zhou , Y. Zheng , A. K. Smith , N. P. Daskalakis , A. Ratanatharathorn , M. Uddin , C. M. Nievergelt , A. E. Ashley‐Koch , D. G. Baker , J. C. Beckham , M. E. Garrett , M. P. Boks , E. Geuze , G. A. Grant , M. A. Hauser , R. C. Kessler , N. A. Kimbrel , A. X. Maihofer , C. E. Marx , X. ‐. J. Qin , V. B. Risbrough , B. P. F. Rutten , M. B. Stein , R. J. Ursano , E. Vermetten , C. H. Vinkers , E. B. Ware , A. Stone , S. A. Schichman , R. E. Mcglinchey , W. P. Milberg , J. P. Hayes , M. Verfaellie , Clin. Epigenet. 2020, 12 , 46.
45 K. R. Kumar , M. J. Cowley , R. L. Davis , Semin. Thromb. Hemostasis 2019, 45 , 661.
46 E. L. Van Dijk , H. Auger , Y. Jaszczyszyn , C. Thermes , Trends Genet. 2014, 30 , 418.25108476
47 L. J. Smyth , A. P. Maxwell , K. A. Benson , J. Kilner , G. J. Mckay , A. J. Mcknight , BMC Res. Notes 2018, 11 , 767.30373632
48 A. l Harrasi , I , R. Al‐Yahyai , M. W. Yaish , Methods Mol. Biol. 2017, 1631 , 121.28735394
49 B. I. Laufer , H. Hwang , J. M. Jianu , C. E. Mordaunt , I. F. Korf , I. Hertz‐Picciotto , J. M. Lasalle , Hum. Mol. Genet. 2021, 29 , 3465.33001180
50 E. E. Schadt , S. Turner , A. Kasarskis , Hum. Mol. Genet. 2010, 19 , R227.20858600
51 E. L. Van Dijk , Y. Jaszczyszyn , D. Naquin , C. Thermes , Trends Genet. 2018, 34 , 666.29941292
52 J. Schmidt , F. Blessing , L. Fimpler , F. Wenzel , Clin. Lab 2020, 66 , 191114.
53 F. Kraft , I. Kurth , Int. J. Biochem. Cell Biol. 2020, 126 , 105799.32629027
54 D. Pushkarev , N. F. Neff , S. R. Quake , Nat. Biotechnol. 2009, 27 , 847.19668243
55 N. Kondratyev , A. Golov , M. Alfimova , T. Lezheiko , V. Golimbet , Clin. Epigenet. 2018, 10 , 130.
56 J. B. Kodal , C. J. Kobylecki , S. Vedel‐Krogh , B. G. Nordestgaard , S. E. Bojesen , Eur. Respir. J. 2018, 51 , 1701512.29348151
57 K. Kemp Jacobsen , J. S. Johansen , A. Mellemgaard , S. E. Bojesen , PLoS One 2019, 14 , e0211745.30730943
58 G. Kaur , R. Begum , S. Thota , S. Batra , Arch. Toxicol. 2019, 93 , 2715.31555878
59 M. Ahsan , W. E. Ek , M. Rask‐Andersen , T. Karlsson , A. Lind‐Thomsen , S. Enroth , U. Gyllensten , Å. Johansson , PLoS Genet. 2017, 13 , e1007005.28915241
60 D. S. Paul , S. Beck , Trends Mol. Med. 2014, 20 , 541.25092140
61 J. D. Holbrook , R.‐C. Huang , S. J. Barton , R. Saffery , K. A. Lillycrop , Epigenomics 2017, 9 , 1143.28749184
62 D. L. Mccartney , R. F. Hillary , A. J. Stevenson , S. J. Ritchie , R. M. Walker , Q. Zhang , S. W. Morris , M. L. Bermingham , A. Campbell , A. D. Murray , H. C. Whalley , C. R. Gale , D. J. Porteous , C. S. Haley , A. F. Mcrae , N. R. Wray , P. M. Visscher , A. M. Mcintosh , K. L. Evans , I. J. Deary , R. E. Marioni , Genome Biol. 2018, 19 , 136.30257690
63 M. G. Gottschalk , K. Domschke , M. A. Schiele , Front. Psychiatry 2020, 11 , 163.32265751
64 M. Ben Maamar , E. Nilsson , J. L. M. Thorson , D. Beck , M. K. Skinner , Environ. Res. 2021, 192 , 110279.33039529
65 S. Wahl , A. Drong , B. Lehne , M. Loh , W. R. Scott , S. Kunze , P.‐C. Tsai , J. S. Ried , W. Zhang , Y. Yang , S. Tan , G. Fiorito , L. Franke , S. Guarrera , S. Kasela , J. Kriebel , R. C. Richmond , M. Adamo , U. Afzal , M. Ala‐Korpela , B. Albetti , O. Ammerpohl , J. F. Apperley , M. Beekman , P. A. Bertazzi , S. L Black , C. Blancher , M.‐J. Bonder , M. Brosch , M. Carstensen‐Kirberg , A. J. M. De Craen , S. De Lusignan , A. Dehghan , M. Elkalaawy , K. Fischer , O. H. Franco , T. R. Gaunt , J. Hampe , M. Hashemi , A. Isaacs , A. Jenkinson , S. Jha , N. Kato , V. Krogh , M. Laffan , C. Meisinger , T. Meitinger , Z. Y. Mok , V. Motta , H. K. Ng , Z. Nikolakopoulou , G. Nteliopoulos , S. Panico , N. Pervjakova , H. Prokisch , W. Rathmann , M. Roden , F. Rota , M. A. Rozario , J. K. Sandling , C. Schafmayer , K. Schramm , R. Siebert , P. E Slagboom , P. Soininen , L. Stolk , K. Strauch , E.‐S. Tai , L. Tarantini , B. Thorand , E. F. Tigchelaar , R. Tumino , A. G. Uitterlinden , C. Van Duijn , J. B. J. Van Meurs , P. Vineis , A. R. Wickremasinghe , C. Wijmenga , T.‐P. Yang , W. Yuan , A. Zhernakova , R. L. Batterham , G. D. Smith , P. Deloukas , B. T. Heijmans , C. Herder , A. Hofman , C. M. Lindgren , L. Milani , P. Van Der Harst , A. Peters , T. Illig , C. L. Relton , M. Waldenberger , M.‐R. Järvelin , V. Bollati , R. Soong , T. D. Spector , J. Scott , M. I. Mccarthy , P. Elliott , J. T. Bell , G. Matullo , C. Gieger , J. S. Kooner , H. Grallert , J. C. Chambers , Nature 2017, 541 , 81.28002404
66 A. Vasanthakumar , J. W. Davis , K. Idler , J. F. Waring , E. Asque , B. Riley‐Gillis , S. Grosskurth , G. Srivastava , S. Kim , K. Nho , K. N. H. Nudelman , K. Faber , Y. Sun , T. M. Foroud , K. Estrada , L. G. Apostolova , Q. S. Li , A. J. Saykin , Clin. Epigenet. 2020, 12 , 84.
67 C. E. Mordaunt , J. M. Jianu , B. I. Laufer , Y. Zhu , H. Hwang , K. W. Dunaway , K. M. Bakulski , J. I. Feinberg , H. E. Volk , K. Lyall , L. A. Croen , C. J. Newschaffer , S. Ozonoff , I. Hertz‐Picciotto , M. D Fallin , R. J. Schmidt , J. M. Lasalle , Genome Med. 2020, 12 , 88.33054850
68 J. A. Heiss , H. Brenner , Clin. Epigenet. 2017, 9 , 24.
69 Y. Pan , G. Liu , F. Zhou , B. Su , Y. Li , Clin. Exp. Med. 2018, 18 , 1.28752221
70 C. L. Miranda Furtado , M. C. Dos Santos Luciano , R. D. Silva Santos , G. P. Furtado , M. O. Moraes , C. Pessoa , Epigenetics 2019, 14 , 1164.31282279
71 K. A. Gelato , Z. Shaikhibrahim , M. Ocker , B. Haendler , Expert Opin. Ther. Targets 2016, 20 , 783.26799480
72 S. Patnaik , Anupriya , Front. Pharmacol. 2019, 10 , 588.31244652
73 S. E. Reese , C.‐J. Xu , H. T. Den Dekker , M. K. Lee , S. Sikdar , C. Ruiz‐Arenas , S. K. Merid , F. I. Rezwan , C. M. Page , V. Ullemar , P. E. Melton , S. S. Oh , I. V. Yang , K. Burrows , C. Söderhäll , D. D. Jima , L. Gao , R. Arathimos , L. K. Küpers , M. Wielscher , P. Rzehak , J. Lahti , C. Laprise , A.‐M. Madore , J. Ward , B. D. Bennett , T. Wang , D. A. Bell , J. M. Vonk , S. E. Håberg , S. Zhao , R. Karlsson , E. Hollams , D. Hu , A. J. Richards , A. Bergström , G. C. Sharp , J. F. Felix , M. Bustamante , O. Gruzieva , R. L. Maguire , F. Gilliland , N. Baïz , E. A. Nohr , E. Corpeleijn , S. Sebert , W. Karmaus , V. Grote , E. Kajantie , M. C. Magnus , A. K. Örtqvist , C. Eng , A. H. Liu , I. Kull , V. W. V. Jaddoe , J. Sunyer , J. Kere , C. Hoyo , I. Annesi‐Maesano , S. H. Arshad , B. Koletzko , B. Brunekreef , E. B. Binder , K. Räikkönen , E. Reischl , J. W. Holloway , M.‐R. Jarvelin , H. Snieder , N. Kazmi , C. V. Breton , S. K. Murphy , G. Pershagen , J. M. Anto , C. L. Relton , D. A. Schwartz , E. G. Burchard , R.‐C. Huang , W. Nystad , C. Almqvist , A. J Henderson , E. Melén , L. Duijts , G. H. Koppelman , S. J. London , J. Allergy Clin. Immunol. 2019, 143 , 2062.30579849
74 N. A. Molfino , D. Gossage , R. Kolbeck , J. M. Parker , G. P. Geba , Clin. Exp. Allergy 2012, 42 , 712.22092535
75 J. W. Ng , L. M. Barrett , A. Wong , D. Kuh , G. D. Smith , C. L. Relton , Genome Biol. 2012, 13 , 246.22747597
76 B. Wang , A. L. Destefano , H. Lin , BMC Proc. 2018, 12 , 28.30275882
77 H. E. Nustad , M. Almeida , A. J. Canty , M. Leblanc , C. M. Page , P. E. Melton , BMC Genet. 2018, 19 , 77.30255778
78 J. Krushkal , T. Silvers , W. C. Reinhold , D. Sonkin , S. Vural , J. Connelly , S. Varma , P. S. Meltzer , M. Kunkel , A. Rapisarda , D. Evans , Y. Pommier , B. A. Teicher , Clin. Epigenet. 2020, 12 , 93.
79 D. Liu , L. Zhao , Z. Wang , X. Zhou , X. Fan , Y. Li , J. Xu , S. Hu , M. Niu , X. Song , Y. Li , L. Zuo , C. Lei , M. Zhang , G. Tang , M. Huang , N. Zhang , L. Duan , H. Lv , M. Zhang , J. Li , L. Xu , F. Kong , R. Feng , Y. Jiang , Nucleic Acids Res. 2019, 47 , D989.30321400
80 M. Li , D. Zou , Z. Li , R. Gao , J. Sang , Y. Zhang , R. Li , L. Xia , T. Zhang , G. Niu , Y. Bao , Z. Zhang , Nucleic Acids Res. 2019, 47 , D983.30364969
81 Z. Xiong , M. Li , F. Yang , Y. Ma , J. Sang , R. Li , Z. Li , Z. Zhang , Y. Bao , Nucleic Acids Res. 2020, 48 , D890.31584095
82 D. L. Scott , F. Wolfe , T. W. Huizinga , Lancet 2010, 376 , 1094.20870100
83 M. V. Nemtsova , D. V. Zaletaev , I. V. Bure , D. S. Mikhaylenko , E. B. Kuznetsova , E. A. Alekseeva , M. I. Beloukhova , A. A. Deviatkin , A. N. Lukashev , A. A. Zamyatnin , Front. Genet. 2019, 10 , 570.31258550
84 C.‐G. Miao , Y.‐Y. Yang , X. He , J. Li , Cell. Signalling 2013, 25 , 875.23277203
85 S. Horsburgh , M. Ciechomska , S. O'reilly , Epigenomics 2017, 9 , 595.28447857
86 M. Vecellio , H. Wu , Q. Lu , C. Selmi , Clin. Rheumatol. 2021, 40 , 459.32613397
87 S. Raychaudhuri , C. Sandor , E. A. Stahl , J. Freudenberg , H.‐S. Lee , X. Jia , L. Alfredsson , L. Padyukov , L. Klareskog , J. Worthington , K. A. Siminovitch , S.‐C. Bae , R. M. Plenge , P. K. Gregersen , P. I. W. De Bakker , Nat. Genet. 2012, 44 , 291.22286218
88 V. Anaparti , P. Agarwal , I. Smolik , N. Mookherjee , H. El‐Gabalawy , J. Rheumatol. 2020, 47 , 1614.31676691
89 Y. Liu , M. J. Aryee , L. Padyukov , M. D. Fallin , E. Hesselberg , A. Runarsson , L. Reinius , N. Acevedo , M. Taub , M. Ronninger , K. Shchetynsky , A. Scheynius , J. Kere , L. Alfredsson , L. Klareskog , T. J. Ekström , A. P. Feinberg , Nat. Biotechnol. 2013, 31 , 142.23334450
90 H. U. Scherer , T. Häupl , G. R. Burmester , J. Autoimmun. 2020, 110 , 102400.31980337
91 A. Julià , D. Absher , M. López‐Lasanta , N. Palau , A. Pluma , L. Waite Jones , J. R. Glossop , W. E. Farrell , R. M. Myers , S. Marsal , Hum. Mol. Genet. 2017, 26 , 2803.28475762
92 F. A. H. Cooles , A. E. Anderson , A. Skelton , A. G. Pratt , M. S. Kurowska‐Stolarska , I. Mcinnes , C. M. U. Hilkens , J. D. Isaacs , Front. Immunol. 2018, 9 , 755.29867920
93 A. Rossin , G. Miloro , A.‐O. Hueber , Cancers 2019, 11 , 639.
94 M. Soubrier , C. Lukas , J. Sibilia , B. Fautrel , F. Roux , L. Gossec , S. Patternotte , M. Dougados , Ann. Rheum. Dis. 2011, 70 , 611.21242235
95 A. Gaffo , K. G. Saag , J. R. Curtis , Am. J. Health Syst. Pharm. 2006, 63 , 2451.17158693
96 S. Zhao , E. Mysler , R. J. Moots , Immunotherapy 2018, 10 , 433.29482402
97 D. Plant , A. Webster , N. Nair , J. Oliver , S. L. Smith , S. Eyre , K. L. Hyrich , A. G. Wilson , A. W. Morgan , J. D. Isaacs , J. Worthington , A. Barton , Arthritis Rheumatol. 2016, 68 , 1353.26814849
98 T. Akinyemiju , A. N. Do , A. Patki , S. Aslibekyan , D. Zhi , B. Hidalgo , H. K. Tiwari , D. Absher , X. Geng , D. K. Arnett , M. R. Irvin , Clin. Epigenet. 2018, 10 , 49.
99 M. G. Saklayen , Curr. Hypertens. Rep. 2018, 20 , 12.29480368
100 R. Dommermuth , K. Ewing , Primary Care 2018, 45 , 109.29406938
101 J. Y. Taylor , E. B. Ware , M. L. Wright , J. A. Smith , S. L. R. Kardia , Biol. Res. Nurs. 2019, 21 , 279.30781968
102 D. Mozaffarian , E. J. Benjamin , A. S. Go , D. K. Arnett , M. J. Blaha , M. Cushman , S. de Ferranti , J.‐P. Després , H. J. Fullerton , V. J. Howard , M. D. Huffman , S. E. Judd , B. M. Kissela , D. T. Lackland , J. H. Lichtman , L. D. Lisabeth , S. Liu , R. H. Mackey , D. B. Matchar , D. K. McGuire , E. R. MohlerIII , C. S. Moy , P. Muntner , M. E. Mussolino , K. Nasir , R. W. Neumar , G. Nichol , L. Palaniappan , D. K. Pandey , M. J. Reeves , C. J. Rodriguez , P. D. Sorlie , J. Stein , A. Towfighi , T. N. Turan , S. S. Virani , J. Z. Willey , D. Woo , R. W. Yeh , M. B. Turner , Circulation 2015, 131 , e29.25520374
103 J. D. Holbrook , Epigenomics 2016, 8 , 741.27010080
104 L. D. Ruiz , M. L. Zuelch , S. M. Dimitratos , R. E. Scherr , Nutrients 2019, 12 , 43.
105 O. Ali , D. Cerjak , J. W. Kent , R. James , J. Blangero , M. A. Carless , Y. Zhang , Epigenetics 2016, 11 , 699.27564309
106 S. Kim , M. Eliot , D. C. Koestler , E. A. Houseman , J. G. Wetmur , J. K. Wiencke , K. T. Kelsey , Epigenomics 2016, 8 , 1185.27529193
107 X. Lu , E. Fraszczyk , T. P. Van Der Meer , M. Van Faassen , V. W. Bloks , I. P. Kema , A. P. Van Beek , S. Li , L. Franke , H.‐J. Westra , X. Xu , X. Huo , H. Snieder , B. H. R. Wolffenbuttel , J. V. Van Vliet‐Ostaptchouk , Environ. Int. 2020, 144 , 106016.32916427
108 M. Das , J. Sha , B. Hidalgo , S. Aslibekyan , A. N. Do , D. Zhi , D. Sun , T. Zhang , S. Li , W. Chen , S. R. Srinivasan , H. K. Tiwari , D. Absher , J. M. Ordovas , G. S. Berenson , D. K. Arnett , M. R. Irvin , PLoS One 2016, 11 , e0145789.26808626
109 L. Fernández‐Rhodes , A. G. Howard , R. Tao , K. L. Young , M. Graff , A. E. Aiello , K. E. North , A. E. Justice , BMC Genet. 2018, 19 , 69.30255772
110 C.‐Q. Lai , L. D. Parnell , C. E. Smith , T. Guo , S. Sayols‐Baixeras , S. Aslibekyan , H. K. Tiwari , M. R. Irvin , C. Bender , D. Fei , B. Hidalgo , P. N. Hopkins , D. M. Absher , M. A. Province , R. Elosua , D. K. Arnett , J. M. Ordovas , Am. J. Clin. Nutr. 2020, 112 , 1200.32930325
111 M. Jiang , J. He , H. Gu , Y. Yang , Y. Huang , X. Xu , L. Liu , Toxicol. Appl. Pharmacol. 2020, 388 , 114871.31881177
112 E. Terán‐Cabanillas , J. Hernández , Inflammation 2017, 40 , 58.27704310
113 J. A. B. Pedroso , A. M. Ramos‐Lobo , J. Donato , Hormones 2019, 18 , 127.30414080
114 O. Ali , D. Cerjak , J. W. Kent , R. James , J. Blangero , M. A. Carless , Y. Zhang , Clin. Epigenet. 2015, 7 , 12.
115 K. A. C. Meeks , P. Henneman , A. Venema , J. Addo , S. Bahendeka , T. Burr , I. Danquah , C. Galbete , M. M. A. M. Mannens , F. P. Mockenhaupt , E. Owusu‐Dabo , C. N. Rotimi , M. B. Schulze , L. Smeeth , J. Spranger , M. H. Zafarmand , A. Adeyemo , C. Agyemang , Int. J. Epidemiol. 2019, 48 , 58.30107520
116 D. S. Albao , E. M. Cutiongco‐de la Paz , M. E. Mercado , A. Lirio , M. Mariano , S. Kim , A. Yangco , J. Melegrito , K. Wad‐Asen , I. I. Gauran , M. A. Francisco , C. Santos‐Acuin , C. David‐Padilla , E. J. Murphy , E. Paz‐Pacheco , M. Seielstad , Hum. Mol. Genet. 2019, 28 , 4208.31691802
117 C. Krause , H. Sievert , C. Geißler , M. Grohs , A. T. El Gammal , S. Wolter , O. Ohlei , F. Kilpert , U. M. Krämer , M. Kasten , C. Klein , G. E. Brabant , O. Mann , H. Lehnert , H. Kirchner , Epigenomics 2019, 11 , 885.31169416
118 M. A. Hall , S. M. Dudek , R. Goodloe , D. C. Crawford , S. A. Pendergrass , P. Peissig , M. Brilliant , C. A. Mccarty , M. D. Ritchie , Pac. Symp. Biocomput. 2014, 200.
119 M. J. Amiot , C. Riva , A. Vinet , Obes. Rev. 2016, 17 , 573.27079631
120 T. S. Han , Y. Y. Al‐Gindan , L. Govan , C. R. Hankey , M. E. J. Lean , Acta Diabetol. 2019, 56 , 947.30927105
121 M. Mamtani , H. Kulkarni , T. D. Dyer , H. H. H. Göring , J. L. Neary , S. A. Cole , J. W. Kent , S. Kumar , D. C. Glahn , M. C. Mahaney , A. G. Comuzzie , L. Almasy , J. E. Curran , R. Duggirala , J. Blangero , M. A. Carless , Clin. Epigenet. 2016, 8 , 6.
122 T. Dayeh , T. Tuomi , P. Almgren , A. Perfilyev , P.‐A. Jansson , V. D. De Mello , J. Pihlajamäki , A. Vaag , L. Groop , E. Nilsson , C. Ling , Epigenetics 2016, 11 , 482.27148772
123 A. D. Pradhan , N. P. Paynter , B. M. Everett , R. J. Glynn , P. Amarenco , M. Elam , H. Ginsberg , W. R. Hiatt , S. Ishibashi , W. Koenig , B. G. Nordestgaard , J.‐C. Fruchart , P. Libby , P. M. Ridker , Am. Heart J. 2018, 206 , 80.30342298
124 A. Arpón , F. I. Milagro , O. Ramos‐Lopez , M. L Mansego , J. L. Santos , J.‐ I. Riezu‐Boj , J. A Martínez , Sci. Rep. 2019, 9 , 2445.30792424
125 R. G. Smith , K. Lunnon , Adv. Exp. Med. Biol. 2017, 978 , 303.28523553
126 K. Lunnon , J. Mill , Am. J. Med. Genet., Part B 2013, 162B , 789.24038819
127 R. Brookmeyer , E. Johnson , K. Ziegler‐Graham , H. M Arrighi , Alzheimers Dement. 2007, 3 , 186.19595937
128 K. M. Bakulski , D. C. Dolinoy , M. A. Sartor , H. L. Paulson , J. R. Konen , A. P. Lieberman , R. L. Albin , H. Hu , L. S. Rozek , J. Alzheimers Dis. 2012, 29 , 571.22451312
129 K. Lunnon , R. Smith , E. Hannon , P. L. De Jager , G. Srivastava , M. Volta , C. Troakes , S. Al‐Sarraj , J. Burrage , R. Macdonald , D. Condliffe , L. W. Harries , P. Katsel , V. Haroutunian , Z. Kaminsky , C. Joachim , J. Powell , S. Lovestone , D. A. Bennett , L. C. Schalkwyk , J. Mill , Nat. Neurosci. 2014, 17 , 1164.25129077
130 J. Lord , C. Cruchaga , Nat. Neurosci. 2014, 17 , 1138.25157507
131 A. R. Smith , R. G. Smith , J. Burrage , C. Troakes , S. Al‐Sarraj , R. N. Kalaria , C. Sloan , A. C. Robinson , J. Mill , K. Lunnon , Neurobiol. Aging 2019, 74 , 70.30439595
132 Z. Gao , H.‐J. Fu , L.‐B. Zhao , Z.‐Y. Sun , Y.‐F. Yang , H.‐Y. Zhu , Exp. Ther. Med. 2018, 15 , 103.29375678
133 S. Warrier , R. Marimuthu , S. Sekhar , G. Bhuvanalakshmi , F. Arfuso , A. K. Das , R. Bhonde , R. Martins , A. Dharmarajan , Int. J. Biochem. Cell Biol. 2016, 75 , 104.27063405
134 L. Jia , J. Piña‐Crespo , Y. Li , Mol. Brain 2019, 12 , 104.31801553
135 R. G. Smith , E. Hannon , P. L. De Jager , L. Chibnik , S. J. Lott , D. Condliffe , A. R. Smith , V. Haroutunian , C. Troakes , S. Al‐Sarraj , D. A. Bennett , J. Powell , S. Lovestone , L. Schalkwyk , J. Mill , K. Lunnon , Alzheimers Dement. 2018, 14 , 1580.29550519
136 Q. S. Li , Y. Sun , T. Wang , Clin. Epigenet. 2020, 12 , 149.
137 J. A. Y. Roubroeks , A. R. Smith , R. G. Smith , E. Pishva , Z. Ibrahim , M. Sattlecker , E. J. Hannon , I. Kłoszewska , P. Mecocci , H. Soininen , M. Tsolaki , B. Vellas , L.‐O. Wahlund , D. Aarsland , P. Proitsi , A. Hodges , S. Lovestone , S. J. Newhouse , R. J. B. Dobson , J. Mill , D. L. A. Van Den Hove , K. Lunnon , Neurobiol. Aging 2020, 95 , 26.32745807
138 B. W. Haas , M. M. Filkowski , R. N. Cochran , L. Denison , A. Ishak , S. Nishitani , A. K. Smith , Proc. Natl. Acad. Sci. USA 2016, 113 , E3816.27325757
139 R. Lardenoije , J. A. Y. Roubroeks , E. Pishva , M. Leber , H. Wagner , A. Iatrou , A. R. Smith , R. G. Smith , L. M. T. Eijssen , L. Kleineidam , A. Kawalia , P. Hoffmann , T. Luck , S. Riedel‐Heller , F. Jessen , W. Maier , M. Wagner , R. Hurlemann , G. Kenis , M. Ali , A. Del Sol , D. Mastroeni , E. Delvaux , P. D. Coleman , J. Mill , B. P. F. Rutten , K. Lunnon , A. Ramirez , D. L. A. Van Den Hove , Clin. Epigenet. 2019, 11 , 164.
140 M. Zhang , G. Schmitt‐Ulms , C. Sato , Z. Xi , Y. Zhang , Y. Zhou , P. St George‐Hyslop , E. Rogaeva , PLoS One 2016, 11 , e0168812.28005991
141 A. Corbett , Front. Biosci. 2015, 7 , 184.
142 P. Chatterjee , D. Roy , N. Rathi , J. Alzheimers Dis. 2018, 61 , 53.29199645
143 Q. Tang , T. Holland‐Letz , A. Slynko , K. Cuk , F. Marme , S. Schott , J. Heil , B. Qu , M. Golatta , M. Bewerunge‐Hudler , C. Sutter , H. Surowy , B. Wappenschmidt , R. Schmutzler , M. Hoth , P. Bugert , C. R. Bartram , C. Sohn , A. Schneeweiss , R. Yang , B. Burwinkel , Oncotarget 2016, 7 , 64191.27577081
144 J. Ferlay , I. Soerjomataram , R. Dikshit , S. Eser , C. Mathers , M. Rebelo , D. M. Parkin , D. Forman , F. Bray , Int. J. Cancer 2015, 136 , E359.25220842
145 A. Johansson , J. M. Flanagan , Trends Cancer Res. 2017, 12 , 19.28955137
146 Z. Xu , J. A. Taylor , Carcinogenesis 2014, 35 , 356.24287154
147 K. Ennour‐Idrissi , D. Dragic , F. Durocher , C. Diorio , BMC Cancer 2020, 20 , 1048.33129307
148 J. E. Rossouw , G. L. Anderson , R. L. Prentice , A. Z. LaCroix , C. Kooperberg , M. L. Stefanick , R. D. Jackson , S. A. A. Beresford , B. V. Howard , K. C. Johnson , J. M. Kotchen , J. Ockene , Writing Group for the Women's Health Initiative Investigators , JAMA, J. Am. Med. Assoc. 2002, 288 , 321.
149 Q. Wu , S. Odwin‐Dacosta , S. Cao , J. D. Yager , W.‐Y. Tang , Toxicol. Appl. Pharmacol. 2019, 367 , 12.30684530
150 Z. Awada , R. Nasr , R. Akika , V. Cahais , C. Cuenin , M. Zhivagui , Z. Herceg , A. Ghantous , N. K. Zgheib , Clin. Epigenet. 2019, 11 , 138.
151 A. Johansson , D. Palli , G. Masala , S. Grioni , C. Agnoli , R. Tumino , M. C. Giurdanella , F. Fasanelli , C. Sacerdote , S. Panico , A. Mattiello , S. Polidoro , M. E. Jones , M. J. Schoemaker , N. Orr , K. Tomczyk , N. Johnson , O. Fletcher , V. Perduca , L. Baglietto , P.‐A. Dugué , M. C. Southey , G. G. Giles , D. R. English , R. L. Milne , G. Severi , S. Ambatipudi , C. Cuenin , V. Chajès , I. Romieu , Z. Herceg , A. J. Swerdlow , P. Vineis , J. M. Flanagan , Clin. Epigenet. 2019, 11 , 66.
152 S. Harlid , Z. Xu , E. Kirk , L. E. Wilson , M. A. Troester , J. A. Taylor , Epigenetics 2019, 14 , 146.30821641
153 B. Y. Hair , Z. Xu , E. L. Kirk , S. Harlid , R. Sandhu , W. R. Robinson , M. C. Wu , A. F. Olshan , K. Conway , J. A. Taylor , M. A. Troester , Breast Cancer Res. Treat. 2015, 151 , 453.25953686
154 J. Shen , R. Song , Y. Ye , X. Wu , W.‐H. Chow , H. Zhao , Obes. Res. Clin. Pract. 2020, 14 , 548.33121895
155 B. Y. Hair , M. A. Troester , S. N. Edmiston , E. A. Parrish , W. R. Robinson , M. C. Wu , A. F. Olshan , T. Swift‐Scanlan , K. Conway , Cancer Epidemiol., Biomarkers Prev. 2015, 24 , 580.25583948
156 G. Severi , M. C. Southey , D. R. English , C.‐H. Jung , A. Lonie , C. Mclean , H. Tsimiklis , J. L. Hopper , G. G. Giles , L. Baglietto , Breast Cancer Res. Treat. 2014, 148 , 665.25407397
157 Z. Guan , H. Yu , K. Cuk , Y. Zhang , H. Brenner , Cancer Epidemiol., Biomarkers Prev. 2019, 28 , 496.30487132
158 R. Yang , K. Pfütze , M. Zucknick , C. Sutter , B. Wappenschmidt , F. Marme , B. Qu , K. Cuk , C. Engel , S. Schott , A. Schneeweiss , H. Brenner , R. Claus , C. Plass , P. Bugert , M. Hoth , C. Sohn , R. Schmutzler , C. R. Bartram , B. Burwinkel , Int. J. Cancer 2015, 136 , 1845.25213452
159 Q. Tang , J. Cheng , X. Cao , H. Surowy , B. Burwinkel , Clin. Epigenet. 2016, 8 , 115.
160 K. Ennour‐Idrissi , D. Dragic , E. Issa , A. Michaud , S.‐L. Chang , L. Provencher , F. Durocher , C. Diorio , Cancers 2020, 12 , 3088.
161 A. Cardenas , J. E. Sordillo , S. L. Rifas‐Shiman , W. Chung , L. Liang , B. A. Coull , M.‐F. Hivert , P. S. Lai , E. Forno , J. C. Celedón , A. A. Litonjua , K. J. Brennan , D. L. Demeo , A. A. Baccarelli , E. Oken , D. R. Gold , Nat. Commun. 2019, 10 , 3095.31300640
162 M. Kabesch , J. Tost , Semin. Immunopathol. 2020, 42 , 43.32060620
163 O. Story Jovanova , I. Nedeljkovic , D. Spieler , R. M. Walker , C. Liu , M. Luciano , J. Bressler , J. Brody , A. J. Drake , K. L. Evans , R. Gondalia , S. Kunze , B. Kuhnel , J. Lahti , R. N. Lemaitre , R. E. Marioni , B. Swenson , J. J. Himali , H. Wu , Y. Li , A. F. Mcrae , T. C. Russ , J. Stewart , Z. Wang , G. Zhang , K.‐H. Ladwig , A. G. Uitterlinden , X. Guo , A. Peters , K. Räikkönen , J. M. Starr , M. Waldenberger , N. R. Wray , E. A. Whitsel , N. Sotoodehnia , S. Seshadri , D. J. Porteous , J. Van Meurs , T. H. Mosley , A. M. Mcintosh , M. M. Mendelson , D. Levy , L. Hou , J. G. Eriksson , M. Fornage , I. J. Deary , A. Baccarelli , H. Tiemeier , N. Amin , JAMA Psychiatry 2018, 75 , 949.29998287
164 L. C. Schecterson , M. Bothwell , Sci. Signaling 2008, 1 , pe50.
165 A. Hüls , C. Robins , K. N. Conneely , P. L. De Jager , D. A. Bennett , M. P. Epstein , T. S. Wingo , A. P. Wingo , Transl. Psychiatry 2020, 10 , 262.32733030
166 K. Tanji , F. Mori , Y. Miki , J. Utsumi , H. Sasaki , A. Kakita , H. Takahashi , K. Wakabayashi , Neurobiol. Dis. 2018, 112 , 14.29330040
167 H. Le‐Niculescu , S. M. Kurian , N. Yehyawi , C. Dike , S. D. Patel , H. J. Edenberg , M. T. Tsuang , D. R. Salomon , J. I. Nurnberger , A. B. Niculescu , Mol. Psychiatry 2009, 14 , 156.18301394
168 J. C. Chambers , M. Loh , B. Lehne , A. Drong , J. Kriebel , V. Motta , S. Wahl , H. R. Elliott , F. Rota , W. R. Scott , W. Zhang , S.‐T. Tan , G. Campanella , M. Chadeau‐Hyam , L. Yengo , R. C. Richmond , M. Adamowicz‐Brice , U. Afzal , K. Bozaoglu , Z. Y. Mok , H. K. Ng , F. Pattou , H. Prokisch , M. A. Rozario , L. Tarantini , J. Abbott , M. Ala‐Korpela , B. Albetti , O. Ammerpohl , P. A. Bertazzi , C. Blancher , R. Caiazzo , J. Danesh , T. R. Gaunt , S. De Lusignan , C. Gieger , T. Illig , S. Jha , S. Jones , J. Jowett , A. J. Kangas , A. Kasturiratne , N. Kato , N. Kotea , S. Kowlessur , J. Pitkäniemi , P. Punjabi , D. Saleheen , C. Schafmayer , P. Soininen , E.‐S. Tai , B. Thorand , J. Tuomilehto , A. R. Wickremasinghe , S. A. Kyrtopoulos , T. J. Aitman , C. Herder , J. Hampe , S. Cauchi , C. L. Relton , P. Froguel , R. Soong , P. Vineis , M.‐R. Jarvelin , J. Scott , H. Grallert , V. Bollati , P. Elliott , M. I. Mccarthy , J. S. Kooner , Lancet Diabetes Endocrinol. 2015, 3 , 526.26095709
169 S. L. Park , Y. M. Patel , L. W. M. Loo , D. J. Mullen , I. A. Offringa , A. Maunakea , D. O. Stram , K. Siegmund , S. E. Murphy , M. Tiirikainen , L. Le Marchand , Clin. Epigenet. 2018, 10 , 110.
170 S. Joseph , N. I. George , B. Green‐Knox , E. L. Treadwell , B. Word , S. Yim , B. Lyn‐Cook , J. Autoimmun. 2019, 96 , 147.30301579
171 E. Fraszczyk , M. Luijten , A. M. W. Spijkerman , H. Snieder , P. F. K. Wackers , V. W. Bloks , C. F. Nicoletti , C. B. Nonino , A. B. Crujeiras , W. A. Buurman , J. W. Greve , S. S. Rensen , B. H. R. Wolffenbuttel , J. V. Van Vliet‐Ostaptchouk , Clin. Epigenet. 2020, 12 , 14.
172 L. Fernández , M. Pérez , R. Olanda , J. M. Orduña , J. Marquez‐Molins , BMC Bioinformatics 2020, 21 , 287.32631226
173 M. Catoni , M. Catoni , J. MF Tsang , A. P. Greco , N. R. Zabet , Nucleic Acids Res. 2018, 46 , e114.29986099
174 D. Almeida , I. Skov , A. Silva , F. Vandin , Q. Tan , R. Röttger , J. Baumbach , Bioinformatics 2017, 33 , 549.27794558
175 P. F. Kuan , J. Song , S. He , Pac. Symp. Biocomput. 2017, 22 , 461.27896998
176 W. Lee , J. S. Morris , Bioinformatics 2016, 32 , 664.26559505
177 J. M. Bhasin , B. Hu , A. H. Ting , Nucleic Acids Res. 2016, 44 , 106.26673711
178 G. Scala , O. Affinito , D. Palumbo , E. Florio , A. Monticelli , G. Miele , L. Chiariotti , S. Cocozza , BMC Bioinf. 2016, 17 , 484.
179 Z. Liu , X. Xiao , W.‐R. Qiu , K.‐C. Chou , Anal. Biochem. 2015, 474 , 69.25596338
180 Z. Wang , X. Li , Y. Jiang , Q. Shao , Q. Liu , B. Chen , D. Huang , PLoS One 2015, 10 , e0132866.26176536
181 Y. Zhang , J. Su , D. Yu , Q. Wu , H. Yan , Annu. Int. Conf. IEEE Eng. Med. Biol. Soc. 2013, 2013 , 655.24109772
182 J. Xu , L. Zhao , D. Liu , S. Hu , X. Song , J. Li , H. Lv , L. Duan , M. Zhang , Q. Jiang , G. Liu , S. Jin , M. Liao , M. Zhang , R. Feng , F. Kong , L. Xu , Y. Jiang , Bioinformatics 2018, 34 , 2657.29566144
183 J. Xu , D. Liu , L. Zhao , Y. Li , Z. Wang , Y. Chen , C. Lei , L. Gao , F. Kong , L. Yuan , Y. Jiang , Sci. Rep. 2016, 6 , 37951.27892496
184 A. Bin Raies , H. Mansour , R. Incitti , V. B. Bajic , PLoS One 2013, 8 , e77848.24147091
185 E. Rahmani , R. Yedidim , L. Shenhav , R. Schweiger , O. Weissbrod , N. Zaitlen , E. Halperin , Bioinformatics 2017, 33 , 1870.28177067
186 S. Pabinger , K. Ernst , W. Pulverer , R. Kallmeyer , A. M. Valdes , S. Metrustry , D. Katic , A. Nuzzo , A. Kriegner , K. Vierlinger , A. Weinhaeusel , PLoS One 2016, 11 , e0160227.27467908
187 H. Chae , S. Lee , S. Seo , D. Jung , H. Chang , K. P. Nephew , S. Kim , Methods 2016, 111 , 64.27477210
188 J. Klughammer , P. Datlinger , D. Printz , N. C. Sheffield , M. Farlik , J. Hadler , G. Fritsch , C. Bock , Cell Rep. 2015, 13 , 2621.26673328
189 W.‐W. Liao , M.‐R. Yen , E. Ju , F.‐M. Hsu , L. Lam , P.‐Y. Chen , BMC Genomics 2015, 16 , S11.
190 Y. Park , M. E. Figueroa , L. S. Rozek , M. A. Sartor , Bioinformatics 2014, 30 , 2414.24836530
191 P. Jiang , K. Sun , F. M. F. Lun , A. M. Guo , H. Wang , K. C. A. Chan , R. W. K. Chiu , Y. M. D. Lo , H. Sun , PLoS One 2014, 9 , e100360.24945300
192 Y. Assenov , F. Müller , P. Lutsik , J. Walter , T. Lengauer , C. Bock , Nat. Methods 2014, 11 , 1138.25262207
193 C.‐C. Chen , S. Xiao , D. Xie , X. Cao , C.‐.X. Song , T. Wang , C. He , S. Zhong , PLoS Comput. Biol. 2013, 9 , e1003367.24339764
194 T. Benoukraf , S. Wongphayak , L. H. A. Hadi , M. Wu , R. Soong , Nucleic Acids Res. 2013, 41 , e55.23268441
195 K. Halachev , H. Bast , F. Albrecht , T. Lengauer , C. Bock , Genome Biol. 2012, 13 , R96.23034089
196 D. Wang , L. Yan , Q. Hu , L. E. Sucheston , M. J. Higgins , C. B. Ambrosone , C. S. Johnson , D. J. Smiraglia , S. Liu , Bioinformatics 2012, 28 , 729.22253290
197 P. Lutsik , L. Feuerbach , J. Arand , T. Lengauer , J. Walter , C. Bock , Nucleic Acids Res. 2011, 39 , W551.21565797
198 R. Louhimo , S. Hautaniemi , Bioinformatics 2011, 27 , 887.21228048
199 Y. Xin , Y. Ge , F. G. Haghighi , Bioinformatics 2011, 27 , 2296.21685051
200 I. Mallona , A. Sierco , M. A. Peinado , Methods Mol. Biol. 2018, 1766 , 123.29605850
201 S. Fan , C. Li , R. Ai , M. Wang , G. S. Firestein , W. Wang , Bioinformatics 2016, 32 , 1773.26883487
202 J. W. Whitaker , Z. Chen , W. Wang , Nat. Methods 2015, 12 , 265.25240437
203 J. Qu , M. Zhou , Q. Song , E. E. Hong , A. D. Smith , Bioinformatics 2013, 29 , 2645.23969133
204 J. He , X. Sun , X. Shao , L. Liang , H. Xie , Bioinformatics 2013, 29 , 2044.23749987
205 N. Aben , D. J. Vis , M. Michaut , L. F. A. Wessels , Bioinformatics 2016, 32 , i413.27587657
206 H. E. Wheeler , K. Aquino‐Michaels , E. R. Gamazon , V. V. Trubetskoy , M. E. Dolan , R. S. Huang , N. J. Cox , H. K. Im , Genet. Epidemiol. 2014, 38 , 402.24799323
207 V. Zazzu , B. Regierer , A. Kühn , R. Sudbrak , H. Lehrach , N. Biotechnol. 2013, 30 , 362.23165094
208 C.‐A. Kapourani , G. Sanguinetti , Bioinformatics 2018, 34 , 2485.29522078
209 S. C. Zheng , C. E. Breeze , S. Beck , A. E. Teschendorff , Nat. Methods 2018, 15 , 1059.30504870
210 C. E. Breeze , D. S. Paul , J. Van Dongen , L. M. Butcher , J. C. Ambrose , J. E. Barrett , R. Lowe , V. K. Rakyan , V. Iotchkova , M. Frontini , K. Downes , W. H. Ouwehand , J. Laperle , P.‐É. Jacques , G. Bourque , A. K. Bergmann , R. Siebert , E. Vellenga , S. Saeed , F. Matarese , J. H. A. Martens , H. G. Stunnenberg , A. E. Teschendorff , J. Herrero , E. Birney , I. Dunham , S. Beck , Cell Rep. 2016, 17 , 2137.27851974
211 M. Van Iterson , D. Cats , P. Hop , B. T. Heijmans , Bioinformatics 2018, 34 , 2142.29420690
212 K. Oros Klein , S. Grinek , S. Bernatsky , L. Bouchard , A. Ciampi , I. Colmegna , J.‐P. Fortin , L. Gao , M.‐F. Hivert , M. Hudson , M. S. Kobor , A. Labbe , J. L. Macisaac , M. J. Meaney , A. M. Morin , K. J. O'donnell , T. Pastinen , M. H. Van Ijzendoorn , G. Voisin , C. M. T. Greenwood , Bioinformatics 2016, 32 , 593.26500152
213 R. Akulenko , M. Merl , V. Helms , PLoS One 2016, 11 , e0159921.27559732
214 D. Almeida , I. Skov , J. Lund , A. Mohammadnejad , A. Silva , F. Vandin , Q. Tan , J. Baumbach , R. Röttger , J. Integr. Bioinform. 2016, 13 , 24.
215 C. Sabbah , G. Mazo , C. Paccard , F. Reyal , P. Hupé , Bioinformatics 2011, 27 , 1693.21493659

